Approved for use through 07/31/2012, OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to resp nd to a collection of information unless it contains a valid OMB control number REQUEST FOR CONTINUED EXAMINATION(RCE)TRANSMITTAL (Submitted Only via EFS-Web) Application Filing Docket Number Art 10/551.947 2005-10-05 05670/LH 2622 Number Date (if applicable) Unit First Named Examiner Togru YAMAKITA Justin P. MISLEH Inventor Name This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. The Instruction Sheet for this form is located at WWW.USPTO.GOV SUBMISSION REQUIRED UNDER 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s). Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked. Consider the arguments in the Appeal Brief or Reply Brief previously filed on Other Enclosed Amendment/Reply Information Disclosure Statement (IDS) Affidavit(s)/ Declaration(s) Other MISCELLANEOUS Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required) Other The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to Denosit Account No. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

PTO/SB/30EFS (07-08)
Approved for use through 07/31/2012 OMB 0651-0031
U.S. Palent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

description. Request for Continued Examination (RCE)

Approved for use Proxyll 07/31/2012 CMB 685-0321

U.S. Palent and Trademack Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Signature of Registered U.S. Patent Practitioner			
Signature	/Douglas Holtz/	Date (YYYY-MM-DD)	2010-02-11
Name	Douglas Holtz	Registration Number	33902

This collection of information is required by 37 CPE 1.114. The information is required to obtain or retain a benefit by the public which to be file (and by the USPF) to proceed a parallelation. Condidentable by governed by 38 USE, 122 and 37 CPE 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including pathering, preparing, and submitting the completed application form to the USPFID. The will vary depending upon the individual case. Any comments on the manuful of time by congrete to complete this from and/or suppositions for reducing ins burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark-Office, U.S. Department of Commence, P.O. Box 14430, Alexandria, Var 2231-1440.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EFS - Web 2.1.15

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the adactived from resident do a patient application or patient. Accordingly, pursuant to the requirements of the Act piesse be advised that: (1) the general authority for the collection of this information is 35 LLS.C. 2(b)(2); (2) I unashing of the information is osciled as voursity, and (3) the privacipal purpose for which he information is used by the LLS. Patient and Trademark Office information, the U.S. Patient and Trademark Office may not be able to process radior examines your submission, which may result in formation of proceedings or abendomment of the application or experience of proceedings or abendomment of the application or experience of the patient.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be discisced to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunat, including disclosures to opposing counsel in the course of settlement negotiation.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need
 for the information in order to perform a contract. Recipients of informations shall be required to comply with the
 requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 5526mh.
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inseption of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under subortly of 44 U.S.C. 2004 and 2006. Sure disclosus shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations.
 - 8. A record from this system of records may be disclosed, as a rotifier use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, by the public if the record was find in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.